首页 > 最新文献

Chinese clinical oncology最新文献

英文 中文
Current status, evolution, and future perspectives in robotic platform systems for prostate cancer treatment: a narrative review. 前列腺癌治疗机器人平台系统的现状、发展和未来展望:综述。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-10-08 DOI: 10.21037/cco-24-47
Flavia Tamborino, Guglielmo Dello Stritto, Gaetano Salzano, Peppino Lannutti, Marco Mascitti, Alessio Digiacomo, Martina Basconi, Rossella Cicchetti, Angelo Orsini, Matteo Ferro, Riccardo De Archangelis, Luigi Schips, Michele Marchioni

Background and objective: Robotic surgery has contributed greatly to the shift from traditional surgery to minimally invasive surgery. Urology is the major field of application of robotic surgery. Several urological procedures, especially radical prostatectomy, benefit from the use of robotic surgery.

Methods: Non-systematic research of the literature was performed using "Robot-assisted radical prostatectomy" and "Robotic platforms" as keywords to understand the actual situation and the future perspectives of this technology in prostate cancer treatment.

Key content and findings: The robotic platform landscape is constantly evolving. DaVinci has always been the mainstay in this field, particularly after the advent of the new single port platforms. New platforms are emerging, providing an alternative option to the well-known DaVinci system. Since in literature, few studies compare the use of different robotic platforms, their application in urological procedures is not yet widely used, for both oncological and non-oncological procedures. Furthermore, artificial intelligence begins to play a role in this landscape and could be useful for future developments. So further studies are warranted to give a full comprehension of the whole scenario.

Conclusions: This review aims to analyze the current state of the use of robotic platforms in urology, particularly in radical prostatectomy, and to understand the evolution.

背景和目的:机器人手术为传统外科手术向微创外科手术的转变做出了巨大贡献。泌尿外科是机器人手术的主要应用领域。一些泌尿外科手术,尤其是根治性前列腺切除术,得益于机器人手术的应用:方法:以 "机器人辅助前列腺癌根治术 "和 "机器人平台 "为关键词,对文献进行非系统研究,以了解该技术在前列腺癌治疗中的实际情况和未来前景:机器人平台的格局在不断演变。达芬奇(DaVinci)一直是该领域的主流,尤其是在新型单孔平台出现之后。新平台不断涌现,为众所周知的达芬奇系统提供了另一种选择。由于文献中很少有研究对不同机器人平台的使用进行比较,因此它们在泌尿外科手术中的应用还不广泛,无论是肿瘤手术还是非肿瘤手术。此外,人工智能已开始在这一领域发挥作用,并可能对未来的发展有所帮助。因此,有必要开展进一步研究,以全面了解整个情况:本综述旨在分析机器人平台在泌尿外科,尤其是根治性前列腺切除术中的应用现状,并了解其发展变化。
{"title":"Current status, evolution, and future perspectives in robotic platform systems for prostate cancer treatment: a narrative review.","authors":"Flavia Tamborino, Guglielmo Dello Stritto, Gaetano Salzano, Peppino Lannutti, Marco Mascitti, Alessio Digiacomo, Martina Basconi, Rossella Cicchetti, Angelo Orsini, Matteo Ferro, Riccardo De Archangelis, Luigi Schips, Michele Marchioni","doi":"10.21037/cco-24-47","DOIUrl":"10.21037/cco-24-47","url":null,"abstract":"<p><strong>Background and objective: </strong>Robotic surgery has contributed greatly to the shift from traditional surgery to minimally invasive surgery. Urology is the major field of application of robotic surgery. Several urological procedures, especially radical prostatectomy, benefit from the use of robotic surgery.</p><p><strong>Methods: </strong>Non-systematic research of the literature was performed using \"Robot-assisted radical prostatectomy\" and \"Robotic platforms\" as keywords to understand the actual situation and the future perspectives of this technology in prostate cancer treatment.</p><p><strong>Key content and findings: </strong>The robotic platform landscape is constantly evolving. DaVinci has always been the mainstay in this field, particularly after the advent of the new single port platforms. New platforms are emerging, providing an alternative option to the well-known DaVinci system. Since in literature, few studies compare the use of different robotic platforms, their application in urological procedures is not yet widely used, for both oncological and non-oncological procedures. Furthermore, artificial intelligence begins to play a role in this landscape and could be useful for future developments. So further studies are warranted to give a full comprehension of the whole scenario.</p><p><strong>Conclusions: </strong>This review aims to analyze the current state of the use of robotic platforms in urology, particularly in radical prostatectomy, and to understand the evolution.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"74"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review. 治疗性抑制胶质瘤和胆管癌中的异柠檬酸脱氢酶突变:新见解和前景--综述。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-22 DOI: 10.21037/cco-24-17
Valeria Internò, Assunta Melaccio, Pasquale Vitale, Roberta Spedaliere, Massimo Buonfantino, Raffaella Messina, Anna Laura Lippolis, Francesco Signorelli, Raffaele Addeo, Francesco Giuliani

Background and objective: The identification of mutation hot spots in the isocitrate dehydrogenase (IDH) genes is one of the most important cancer genome-wide sequencing discoveries with relevant impact in the treatment of some orphan tumors. These genes were mostly found mutated in lower-grade gliomas (LGGs), acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) and in cholangiocarcinoma. This aberrant genomic condition represents a therapeutic target of great interest in cancer research, especially in AML, given the limitations of currently approved therapies in this field. In this review, we investigate the role of IDH mutation and the mutant IDH (mIDH)-targeted therapies for cholangiocarcinoma and glioma.

Methods: Here, we provide an overview of the IDH mutation role and discuss its role in tumorigenesis and progression of some solid cancers, in which the therapeutic strategy can be completely changed thanks to these brand-new therapeutic options.

Key content and findings: The encouraging early clinical data demonstrated to be a proof of concept for investigational mIDH1/2 inhibitors in tumors with a paucity of therapeutic possibilities.

Conclusions: Moreover, we list the most important randomised clinical trials still active with their preliminary results.

背景和目的:异柠檬酸脱氢酶(IDH)基因突变热点的确定是最重要的癌症全基因组测序发现之一,对一些孤儿肿瘤的治疗具有重要影响。这些基因突变主要出现在低级别胶质瘤(LGGs)、急性髓性白血病(AML)、骨髓增生异常综合征(MDS)、骨髓增殖性肿瘤(MPNs)以及胆管癌中。这种异常基因组状况是癌症研究中备受关注的治疗目标,尤其是急性髓细胞性白血病,因为该领域目前批准的疗法存在局限性。在这篇综述中,我们探讨了IDH突变和突变IDH(mIDH)靶向疗法在胆管癌和胶质瘤中的作用。方法:在此,我们概述了IDH突变的作用,并讨论了它在一些实体瘤的肿瘤发生和进展中的作用,由于这些全新的治疗方案,治疗策略可以完全改变:令人鼓舞的早期临床数据证明,在缺乏治疗可能性的肿瘤中,研究性 mIDH1/2 抑制剂是一种概念验证:此外,我们还列出了目前仍在进行的最重要的随机临床试验及其初步结果。
{"title":"Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.","authors":"Valeria Internò, Assunta Melaccio, Pasquale Vitale, Roberta Spedaliere, Massimo Buonfantino, Raffaella Messina, Anna Laura Lippolis, Francesco Signorelli, Raffaele Addeo, Francesco Giuliani","doi":"10.21037/cco-24-17","DOIUrl":"10.21037/cco-24-17","url":null,"abstract":"<p><strong>Background and objective: </strong>The identification of mutation hot spots in the isocitrate dehydrogenase (IDH) genes is one of the most important cancer genome-wide sequencing discoveries with relevant impact in the treatment of some orphan tumors. These genes were mostly found mutated in lower-grade gliomas (LGGs), acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) and in cholangiocarcinoma. This aberrant genomic condition represents a therapeutic target of great interest in cancer research, especially in AML, given the limitations of currently approved therapies in this field. In this review, we investigate the role of IDH mutation and the mutant IDH (mIDH)-targeted therapies for cholangiocarcinoma and glioma.</p><p><strong>Methods: </strong>Here, we provide an overview of the IDH mutation role and discuss its role in tumorigenesis and progression of some solid cancers, in which the therapeutic strategy can be completely changed thanks to these brand-new therapeutic options.</p><p><strong>Key content and findings: </strong>The encouraging early clinical data demonstrated to be a proof of concept for investigational mIDH1/2 inhibitors in tumors with a paucity of therapeutic possibilities.</p><p><strong>Conclusions: </strong>Moreover, we list the most important randomised clinical trials still active with their preliminary results.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"69"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary angiosarcoma of the breast: a literature review. 乳腺原发性血管肉瘤:文献综述。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 Epub Date: 2024-09-05 DOI: 10.21037/cco-24-16
Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien

Background and objective: Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted.

Methods: A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence.

Key content and findings: A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA.

Conclusions: Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.

背景和目的:原发性乳腺血管肉瘤(PBA)是一种极其罕见的异质性疾病。PBA 诊断困难,预后较差。为了更好地了解这种疾病并为 PBA 患者提供循证治疗,我们对已发表的英文文献进行了综述:方法:按照 PRISMA 协议进行文献综述。按照预先确定的策略,在 Medline 和 Cochrane 数据库中检索了 2023 年 9 月有关 PBA 患者的英文文章。根据科学证据的层次对文章进行分类和评估:共检索到 255 篇文章,其中 137 篇符合纳入最终分析的标准,共纳入 1,888 名患者。目前尚未发现专门针对 PBA 的前瞻性随机试验。本文概述了目前有关 PBA 的流行病学、病因学、基因组特征、临床表现、诊断、治疗和预后的最全面证据:尽管目前的证据主要来自于回顾性研究、数据库分析和病例报告,但我们还是利用这些信息解决了有关PBA最佳患者管理方法的重要临床问题。完全手术切除仍然是治疗 PBA 的主要方法。然而,辅助疗法的有效性仍不明确。这篇叙事性综述强调了迫切需要进行更严格设计的研究,以加强 PBA 的管理和治疗策略。
{"title":"Primary angiosarcoma of the breast: a literature review.","authors":"Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien","doi":"10.21037/cco-24-16","DOIUrl":"10.21037/cco-24-16","url":null,"abstract":"<p><strong>Background and objective: </strong>Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted.</p><p><strong>Methods: </strong>A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence.</p><p><strong>Key content and findings: </strong>A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA.</p><p><strong>Conclusions: </strong>Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"68"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma. 将免疫疗法/靶向疗法与肝动脉化疗灌注相结合,治疗晚期肝细胞癌患者。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21037/cco-23-159
Sam Y Son, Hooman Yarmohammadi
{"title":"Combining immunotherapy/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma.","authors":"Sam Y Son, Hooman Yarmohammadi","doi":"10.21037/cco-23-159","DOIUrl":"https://doi.org/10.21037/cco-23-159","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 5","pages":"79"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term outcomes in obese and non-obese patients undergoing transperitoneal laparoscopic adrenalectomy for benign or malignant adrenal diseases: an updated systematic review and meta-analysis. 接受经腹腔镜肾上腺切除术治疗良性或恶性肾上腺疾病的肥胖和非肥胖患者的短期疗效:最新系统综述和荟萃分析。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21037/cco-24-55
Maurizio Zizzo, Andrea Morini, Magda Zanelli, Chiara Grasselli, Francesca Sanguedolce, Andrea Palicelli, Giuseppe Broggi, Nektarios I Koufopoulos, Lucia Mangone, Melissa Nardecchia, Angelo Cormio, Rosario Caltabiano, Giulia Besutti, Stefano Ascani, Massimiliano Fabozzi

Background: Transperitoneal laparoscopic adrenalectomy (TLA) is the most frequently chosen approach in adrenal surgery. At present, impact of obesity on patient outcomes following adrenal surgery is frequently under discussion. We intended to offer updated evidence thanks to a comparison between intraoperative and perioperative outcomes in non-obese and obese patients, who underwent TLA for benign or malignant adrenal diseases.

Methods: Our systematic review made use of Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) guidelines. Articles of interest turned out from a search with PubMed/MEDLINE, Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials-CENTRAL), Web of Science (Science and Social Science Citation Index), and Scopus databases. We evaluated two groups of outcomes: intraoperative (operative time, intraoperative complications rate, estimated blood loss (EBL), transfusion rate, conversion to open surgery rate) and postoperative (overall postoperative complications rate, major postoperative complications rate, length of hospital stay). RevMan (Computer program) Version 5.4 was used to perform the meta-analysis. The heterogeneity of the included studies in the meta-analysis was assessed by using the I2 statist.

Results: The 8 included comparative studies (1,646 patients: 995 non-obese versus 651 obese) had a time frame of approximately 30 years (1994-2020) and an observational nature. Meta-analysis showed no differences in terms of operative time, intraoperative complications rate, EBL, transfusion rate, conversion to open surgery rate, overall postoperative complications rate, major (Clavien-Dindo ≥ III) postoperative complications rate, length of hospital stay between non-obese and obese populations.

Conclusions: We can say that obesity does not impact TLA safety and effectiveness. Due to biases among meta-analyzed studies (small overall sample size and small number of events analyzed, in particular), careful interpretation is needed to interpret our results. Additional randomized, possibly multi-center trials may contribute to confirm our results.

背景:经腹腔镜肾上腺切除术(TLA)是肾上腺手术中最常用的方法。目前,肥胖对肾上腺手术后患者预后的影响经常被讨论。我们希望通过比较因良性或恶性肾上腺疾病而接受 TLA 手术的非肥胖患者和肥胖患者的术中和围手术期结果来提供最新证据:我们的系统综述采用了系统综述和元分析首选报告项目(PRISMA)指南。我们在 PubMed/MEDLINE、Cochrane 图书馆(Cochrane 系统综述数据库、Cochrane 对照试验中央注册中心-CENTRAL)、Web of Science(科学与社会科学引文索引)和 Scopus 数据库中检索了感兴趣的文章。我们评估了两组结果:术中(手术时间、术中并发症发生率、估计失血量(EBL)、输血率、转为开放手术率)和术后(术后总体并发症发生率、术后主要并发症发生率、住院时间)。RevMan(计算机程序)5.4版用于进行荟萃分析。荟萃分析中纳入研究的异质性采用 I2 统计量进行评估:所纳入的 8 项比较研究(1 646 名患者:995 名非肥胖患者与 651 名肥胖患者)的时间跨度约为 30 年(1994-2020 年),且均为观察性研究。Meta分析表明,非肥胖和肥胖人群在手术时间、术中并发症发生率、EBL、输血率、转为开放手术率、术后总并发症发生率、主要(Clavien-Dindo≥III)术后并发症发生率、住院时间等方面均无差异:我们可以说,肥胖不会影响 TLA 的安全性和有效性。由于荟萃分析研究之间存在偏差(特别是总体样本量小和分析的事件数量少),因此需要对我们的结果进行仔细解读。更多的随机试验(可能是多中心试验)可能有助于证实我们的结果。
{"title":"Short-term outcomes in obese and non-obese patients undergoing transperitoneal laparoscopic adrenalectomy for benign or malignant adrenal diseases: an updated systematic review and meta-analysis.","authors":"Maurizio Zizzo, Andrea Morini, Magda Zanelli, Chiara Grasselli, Francesca Sanguedolce, Andrea Palicelli, Giuseppe Broggi, Nektarios I Koufopoulos, Lucia Mangone, Melissa Nardecchia, Angelo Cormio, Rosario Caltabiano, Giulia Besutti, Stefano Ascani, Massimiliano Fabozzi","doi":"10.21037/cco-24-55","DOIUrl":"10.21037/cco-24-55","url":null,"abstract":"<p><strong>Background: </strong>Transperitoneal laparoscopic adrenalectomy (TLA) is the most frequently chosen approach in adrenal surgery. At present, impact of obesity on patient outcomes following adrenal surgery is frequently under discussion. We intended to offer updated evidence thanks to a comparison between intraoperative and perioperative outcomes in non-obese and obese patients, who underwent TLA for benign or malignant adrenal diseases.</p><p><strong>Methods: </strong>Our systematic review made use of Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) guidelines. Articles of interest turned out from a search with PubMed/MEDLINE, Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials-CENTRAL), Web of Science (Science and Social Science Citation Index), and Scopus databases. We evaluated two groups of outcomes: intraoperative (operative time, intraoperative complications rate, estimated blood loss (EBL), transfusion rate, conversion to open surgery rate) and postoperative (overall postoperative complications rate, major postoperative complications rate, length of hospital stay). RevMan (Computer program) Version 5.4 was used to perform the meta-analysis. The heterogeneity of the included studies in the meta-analysis was assessed by using the I2 statist.</p><p><strong>Results: </strong>The 8 included comparative studies (1,646 patients: 995 non-obese versus 651 obese) had a time frame of approximately 30 years (1994-2020) and an observational nature. Meta-analysis showed no differences in terms of operative time, intraoperative complications rate, EBL, transfusion rate, conversion to open surgery rate, overall postoperative complications rate, major (Clavien-Dindo ≥ III) postoperative complications rate, length of hospital stay between non-obese and obese populations.</p><p><strong>Conclusions: </strong>We can say that obesity does not impact TLA safety and effectiveness. Due to biases among meta-analyzed studies (small overall sample size and small number of events analyzed, in particular), careful interpretation is needed to interpret our results. Additional randomized, possibly multi-center trials may contribute to confirm our results.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 5","pages":"67"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triple combination of hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors for treatment of advanced hepatocellular carcinoma: more robust evidence is still needed. 肝动脉灌注化疗、免疫检查点抑制剂和酪氨酸激酶抑制剂三联疗法治疗晚期肝细胞癌:仍需更有力的证据。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21037/cco-23-155
Mohammad Saeid Rezaee-Zavareh, Ju Dong Yang
{"title":"Triple combination of hepatic arterial infusion chemotherapy, immune checkpoint inhibitors, and tyrosine kinase inhibitors for treatment of advanced hepatocellular carcinoma: more robust evidence is still needed.","authors":"Mohammad Saeid Rezaee-Zavareh, Ju Dong Yang","doi":"10.21037/cco-23-155","DOIUrl":"https://doi.org/10.21037/cco-23-155","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 5","pages":"77"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The TRIPLET study: more is better? TRIPLET 研究:越多越好?
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21037/cco-23-158
Salim I Khakoo
{"title":"The TRIPLET study: more is better?","authors":"Salim I Khakoo","doi":"10.21037/cco-23-158","DOIUrl":"https://doi.org/10.21037/cco-23-158","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 5","pages":"78"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination checkpoint inhibition, angiogenic inhibition and hepatic artery infusion chemotherapy for disease control of advanced hepatocellular carcinoma. 联合检查点抑制、血管生成抑制和肝动脉灌注化疗,控制晚期肝细胞癌的病情。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-10-01 DOI: 10.21037/cco-23-149
Sayed Imtiaz, Mohd Raashid Sheikh
{"title":"Combination checkpoint inhibition, angiogenic inhibition and hepatic artery infusion chemotherapy for disease control of advanced hepatocellular carcinoma.","authors":"Sayed Imtiaz, Mohd Raashid Sheikh","doi":"10.21037/cco-23-149","DOIUrl":"https://doi.org/10.21037/cco-23-149","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 5","pages":"76"},"PeriodicalIF":2.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Befotertinib: one more drug targeting EGFR-the more may be the merrier. 贝福替尼:又一种靶向表皮生长因子受体的药物--多多益善。
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-13 DOI: 10.21037/cco-24-50
Guilherme Sacchi de Camargo Correia, Yanyan Lou, Rami Manochakian
{"title":"Befotertinib: one more drug targeting EGFR-the more may be the merrier.","authors":"Guilherme Sacchi de Camargo Correia, Yanyan Lou, Rami Manochakian","doi":"10.21037/cco-24-50","DOIUrl":"https://doi.org/10.21037/cco-24-50","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AB068. Psychiatric disorder in central nervous system tumor patients and its related factors. AB068.中枢神经系统肿瘤患者的精神障碍及其相关因素
IF 2.1 4区 医学 Q3 ONCOLOGY Pub Date : 2024-08-01 DOI: 10.21037/cco-24-ab068
Feranindhya Agiananda, Tiara Aninditha, Henry Riyanto Sofyan, Irma Savitri, Artasya Karnasih, Putri Air Puspaseruni, Chelsea Kristiniawati Putri

Background: Patients of central nervous system (CNS) tumors have a potential to develop psychiatric disorder. These may present resulting from tumor mass, edema, or patient's failure to adapt to their illness and treatment. The presence of psychiatric disorders may cause disability, decreased daily functioning, reduced quality of life, and even death. In order to provide adequate treatment to patients with CNS tumors, it's important to evaluate the type of psychiatric disorder in patients with spinal and brain tumors. This study aimed to investigate the prevalence of psychiatric disorder dan related factors that exist in patients with brain and spinal tumors.

Methods: In a study conducted at Cipto Mangunkusumo General Hospital from January to December 2023, factors associated with psychiatric disorders in patients with CNS tumors were investigated. The analysis included a total of 161 subjects from inpatient settings. In depth interview was utilized to assess psychiatric disorder. Data analyses were carried out using the Chi-square and Fisher's exact test to assess the relationship between locations of tumor, neurological deficits, and psychiatric disorders.

Results: There were 161 subjects with mean age of 48.86±13.13 years, mostly women (59.0%). Patients with spinal tumor have more psychiatric disorders compared to their counterpart with intracranial tumor (79.1% and 76.3% respectively), while the most common psychiatric disorder was adjustment disorder. There is no significant relationship between tumor location and psychiatric disorder. In both patients with intracranial and spinal tumors, the most common neurological deficit was cancer pain (88.2%). However, bivariate analysis showed that among the neurological deficits found in the CNS tumor patients, dysphagia (P=0.02) and incontinence (P=0.02) have significant relationship with depression, while pain (P=0.02) and cognitive dysfunction (P=0.01) have significant relationship with adjustment disorder. It also showed that pain (P<0.001), cognitive dysfunction (P=0.002), and seizure (P=0.03) have significant relationship with organic mental disorder.

Conclusions: Dysphagia, incontinence, pain, cognitive disfunction, and seizure were identified as risk factors for psychiatric disorders in intracranial and spinal tumor patients. The finding underscores the importance of screening and comprehensive psychiatric evaluations in patients with CNS tumors, as psychiatric symptoms may significantly impact their quality of life and treatment outcomes.

背景:中枢神经系统(CNS)肿瘤患者有可能出现精神障碍。这些症状可能因肿瘤肿块、水肿或患者无法适应疾病和治疗而出现。精神障碍的出现可能导致残疾、日常功能下降、生活质量降低,甚至死亡。为了给中枢神经系统肿瘤患者提供适当的治疗,评估脊髓和脑肿瘤患者的精神障碍类型非常重要。本研究旨在调查脑肿瘤和脊髓肿瘤患者中精神障碍的发生率和相关因素:这项研究于 2023 年 1 月至 12 月在 Cipto Mangunkusumo 综合医院进行,调查了中枢神经系统肿瘤患者精神障碍的相关因素。分析对象包括161名住院病人。采用深度访谈法评估精神障碍。采用卡方检验(Chi-square)和费雪精确检验(Fisher's exact)对数据进行分析,以评估肿瘤位置、神经功能缺损和精神障碍之间的关系:161名受试者的平均年龄为(48.86±13.13)岁,大部分为女性(59.0%)。与颅内肿瘤患者相比,脊柱肿瘤患者有更多的精神障碍(分别为 79.1%和 76.3%),而最常见的精神障碍是适应障碍。肿瘤位置与精神障碍之间没有明显关系。在颅内肿瘤和脊柱肿瘤患者中,最常见的神经功能缺损是癌痛(88.2%)。然而,双变量分析显示,在中枢神经系统肿瘤患者的神经功能缺损中,吞咽困难(P=0.02)和大小便失禁(P=0.02)与抑郁有显著关系,而疼痛(P=0.02)和认知功能障碍(P=0.01)与适应障碍有显著关系。研究还显示,疼痛(PConclusions:吞咽困难、大小便失禁、疼痛、认知功能障碍和癫痫发作被确定为颅内肿瘤和脊柱肿瘤患者精神障碍的危险因素。这一发现强调了对中枢神经系统肿瘤患者进行筛查和全面精神评估的重要性,因为精神症状可能会严重影响患者的生活质量和治疗效果。
{"title":"AB068. Psychiatric disorder in central nervous system tumor patients and its related factors.","authors":"Feranindhya Agiananda, Tiara Aninditha, Henry Riyanto Sofyan, Irma Savitri, Artasya Karnasih, Putri Air Puspaseruni, Chelsea Kristiniawati Putri","doi":"10.21037/cco-24-ab068","DOIUrl":"https://doi.org/10.21037/cco-24-ab068","url":null,"abstract":"<p><strong>Background: </strong>Patients of central nervous system (CNS) tumors have a potential to develop psychiatric disorder. These may present resulting from tumor mass, edema, or patient's failure to adapt to their illness and treatment. The presence of psychiatric disorders may cause disability, decreased daily functioning, reduced quality of life, and even death. In order to provide adequate treatment to patients with CNS tumors, it's important to evaluate the type of psychiatric disorder in patients with spinal and brain tumors. This study aimed to investigate the prevalence of psychiatric disorder dan related factors that exist in patients with brain and spinal tumors.</p><p><strong>Methods: </strong>In a study conducted at Cipto Mangunkusumo General Hospital from January to December 2023, factors associated with psychiatric disorders in patients with CNS tumors were investigated. The analysis included a total of 161 subjects from inpatient settings. In depth interview was utilized to assess psychiatric disorder. Data analyses were carried out using the Chi-square and Fisher's exact test to assess the relationship between locations of tumor, neurological deficits, and psychiatric disorders.</p><p><strong>Results: </strong>There were 161 subjects with mean age of 48.86±13.13 years, mostly women (59.0%). Patients with spinal tumor have more psychiatric disorders compared to their counterpart with intracranial tumor (79.1% and 76.3% respectively), while the most common psychiatric disorder was adjustment disorder. There is no significant relationship between tumor location and psychiatric disorder. In both patients with intracranial and spinal tumors, the most common neurological deficit was cancer pain (88.2%). However, bivariate analysis showed that among the neurological deficits found in the CNS tumor patients, dysphagia (P=0.02) and incontinence (P=0.02) have significant relationship with depression, while pain (P=0.02) and cognitive dysfunction (P=0.01) have significant relationship with adjustment disorder. It also showed that pain (P<0.001), cognitive dysfunction (P=0.002), and seizure (P=0.03) have significant relationship with organic mental disorder.</p><p><strong>Conclusions: </strong>Dysphagia, incontinence, pain, cognitive disfunction, and seizure were identified as risk factors for psychiatric disorders in intracranial and spinal tumor patients. The finding underscores the importance of screening and comprehensive psychiatric evaluations in patients with CNS tumors, as psychiatric symptoms may significantly impact their quality of life and treatment outcomes.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"13 Suppl 1","pages":"AB068"},"PeriodicalIF":2.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1